Metabolic Side Effects of Antipsychotic Medications in Children and Adolescents with Autism Spectrum Disorder (ASD)

Abstract

This publication is intended to provide accurate and authoritative information regarding the subject matter covered. It is sold with the understanding that the publisher is not engaged in rendering medical, psychological, financial, legal, or other professional services. The recommended doses of medications cited in this newsletter are not meant to serve as a guide for prescribing of medications. Physicians, please check the manufacturer's product information sheet or the PHYSICIAN'S DESK REFERENCE for further information and contraindications. 1 • CAPN 21(3) Educational Objectives Upon completion of this activity, participants should be able to: • Review the indications for the use of anti-psychotic medications in children and adolescents with Autism Spectrum Disorders • Develop an understanding of metabolic side effects of anti-psychotic medications in this age group and explore management options for these side effects. Target Audience This CME activity is intended for child and adult psychiatrists, pediatricians and other healthcare professionals with an interest in the psychopharmacology and treatment practices for child and adolescent psychiatric disorders.

Placental DNA methylation levels at CYP2E1 and IRS2 are associated with child outcome in a prospective autism study

“…Four genes were found to be in common between placenta ASD DMRs, brain ASD DMRs and SFARI genetic risk, specifically GADD45B, MC4R, PCDH9 and TBL1XR1 (Betancur et al, 2009;Garbett et al, 2008;Orlik & Halawa, 2016;Tabet et al, 2014).…”

“…GADD45B (growth arrest and DNA-damage-inducible, beta) responds to environmental stress through JNK pathway induced DNA demethylation of neurogenesis and synaptic plasticity at gene promoters (Garbett et al, 2008;Ma et al, 2009;Sultan, Wang, Tront, Liebermann, & Sweatt, 2012). MC4R encodes the membrane-bound melanocortin 4 receptor, implicated in hormone and cell growth pathways in obesity and insulin resistance (Chambers et al, 2008;Orlik & Halawa, 2016;Yeo et al, 1998). PCDH9…”